杜皮鲁玛
奥马佐单抗
美波利祖马布
医学
苯拉唑马布
成本效益
哮喘
质量调整寿命年
内科学
免疫学
免疫球蛋白E
抗体
嗜酸性粒细胞
风险分析(工程)
作者
Abraham Alí-Munive,Elizabeth García,Carlos A. Torres‐Duque,Diana Rey,Laura Alicia Laverde de Botero,Stid Saenz,Maria Paula Avila,Elizabeth Mazo,Sergio Londoño
标识
DOI:10.1080/14737167.2023.2282668
摘要
Background Cost-effectiveness studies evaluate health technologies and help choose treatments. The current study compared dupilumab to omalizumab, mepolizumab, and benralizumab in Colombian adults with severe uncontrolled type 2 asthma.
科研通智能强力驱动
Strongly Powered by AbleSci AI